Status:
UNKNOWN
Treatment Response Prediction System of mCRC Patients Based on CTC
Lead Sponsor:
Fudan University
Conditions:
Colorectal Cancer Stage IV
Circulating Tumor Cell
Eligibility:
All Genders
18-80 years
Brief Summary
This study enrolling patients with metastatic colorectal cancer. Detecting CTC at different points in the treatment process. Descripting the molecular atlas of CTC in mCRC patients. Building and valid...
Eligibility Criteria
Inclusion
- Age 18-80 years;
- histologically proven colorectal liver metastasis
- With liver-dominant disease (extrahepatic metastases limited to lung metastases)
- ECOG 0-1
- A life expectancy of ≥ 3 months
- Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l, platelets≥75×109/l, and international normalized ratio (INR) ≤1.3
- Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl
- Written informed consent for participation in the trial.
Exclusion
- Other previous malignancy within 5 years
- Have metastases other than liver and lung metastases
- Receiving any treatment before first blood collection
Key Trial Info
Start Date :
June 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04917276
Start Date
June 15 2021
End Date
December 1 2025
Last Update
June 8 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.